This invention provides a duplex comprising an oligonucleotide primer and a template, wherein the primer is coupled chemically to a chromophore or fluorophore so as to allow chain extension by a polymerase. In one embodiment, the primer is extended by a polymerase to generate the complement of the template. In a further embodiment, the extended primer is separated from the template for use in a number of methods, including sequencing reactions. methods of generating these compositions of matter are further provided.

PTO Wrapper PDF
Dossier Espace Google
Patent
   RE43096
Priority
Jan 16 1984
Filed
Mar 13 2003
Issued
Jan 10 2012
Expiry
Jan 16 2004
Inventors
Hood, Lero…
Assg.orig
California…
Assg.curr
California…
Entity
Large
Referenced by
0
References
63
Maint.:
all paid
BACKGROUND OF THE IN…
SUMMARY OF THE INVEN…
BRIEF DESCRIPTION OF…
DETAILED DESCRIPTION…
EXAMPLE I
EXAMPLE II
EXAMPLE III
EXAMPLE IV
EXAMPLE V
0. 67. A composition comprising four sets of oligonucleotides, wherein oligonucleotides of each of the four sets are distinguishably labeled with a different type of fluorophore from the oligonucleotides of the other three sets.
0. 66. A mixture comprising a polymerase and a duplex, wherein the duplex comprises an oligonucleotide specifically hybridized to a complementary strand of dna, wherein the oligonucleotide is covalently coupled to a fluorophore so as to allow chain extension by the polymerase.
0. 62. A method of nucleic acid sequence analysis, comprising extending an oligonucleotide along a complementary strand of dna of a duplex by a polymerase to produce a labeled extension product, wherein the duplex comprises the oligonucleotide specifically hybridized to the complementary strand of dna, and wherein the oligonucleotide is covalently coupled to a fluorophore so as to allow chain extension by the polymerase.
0. 64. A dna sequencing method, comprising
extending oligonucleotides of a set of duplexes along hybridized complementary strands of dna by a polymerase to produce a set of labeled extension products, wherein the set of labeled extension products comprises two or more extension products, wherein an extension product comprises an extended oligonucleotide specifically hybridized to a complementary strand of dna,
thereby producing four sets of labeled extension products, wherein the extension products of each set are distinguishably labeled with a different type of fluorophore from the extension products of the other sets.
0. 1. A duplex comprising an oligonucleotide primer and a template, wherein the primer is covalently coupled to a chromophore or fluorophore so as to allow chain extension by a polymerase.
0. 2. A duplex comprising an extended oligonucleotide primer and a template, produced by providing a duplex according to claim 1 and extending the oligonucleotide primer with a polymerase.
0. 3. A single-stranded labeled polynucleotide produced by separating the extended oligonucleotide primer from the duplex of claim 2.
0. 4. A set of duplexes comprising two or more of the duplexes of claim 1.
0. 5. A set of duplexes comprising two or more of the duplexes of claim 2.
0. 6. A set of polynucleotides comprising two or more single-stranded labeled polynucleotides of claim 3.
0. 7. A set of reagents comprising oligonucleotide primers covalently coupled to one or more chromophores or fluorophores so as to allow chain extension by a polymerase, and a polymerase.
0. 8. A single-stranded labeled polynucleotide comprising a first portion and a second portion,
wherein the first portion comprises an oligonucleotide primer covalently coupled to a chromophore or fluorophore; and
wherein the second portion is produced by extension of the first portion along a complementary template.
0. 9. The polynucleotide of claim 8, wherein the chromophore or fluorophore is covalently coupled to the first portion through an amine linkage.
0. 10. The polynucleotide of claim 8, wherein the chromophore or fluorophore is covalently coupled to the first portion at its 5′ end.
0. 11. The duplex of claim 1, prepared by a method comprising hybridizing an oligonucleotide primer to a template, wherein the primer is covalently coupled to a chromophore or fluorophore so as to allow chain extension by a polymerase.
0. 12. The duplex of claim 11, wherein the chromophore or fluorophore is covalently coupled to the primer through an amine linkage.
0. 13. The duplex of claim 11, wherein the chromophore or fluorophore is covalently coupled to the primer at its 5′ end.
0. 14. A single-stranded labeled polynucleotide produced by the method comprising the steps of extending the oligonucleotide primer of the duplex of claim 1 by a polymerase to produce a labeled polynucleotide and separating the labeled polynucleotide from the template.
0. 15. The polynucleotide of claim 14, wherein the chromophore or fluorophore is covalently coupled to the oligonucleotide through an amine linkage.
0. 16. The polynucleotide of claim 14, wherein the chromophore or fluorophore is covalently coupled to the oligonucleotide at its 5′ end.
0. 17. A chain termination dna sequencing method comprising extending the primer of the duplex of claim 1 by a polymerase to produce a labeled polynucleotide, and separating the labeled polynucleotide from the template.
0. 18. A chain termination dna sequencing method comprising extending the primers of the set of duplexes of claim 4 by a polymerase to produce a set of labeled polynucleotides.
0. 19. The chain termination dna sequencing method of claim 18, wherein the set of duplexes comprises four dna sequencing reactions, wherein each labeled polynucleotide is distinguishable by spectral characteristics of the chromophore or fluorophore covalently coupled thereto.
0. 20. The oligonucleotide primer of claim 1, wherein the primer is dna.
0. 21. The oligonucleotide primer of claim 1 wherein the chromophore or fluorophore is detectable by exposure to a high-intensity monochromatic light source.
0. 22. The duplex of either of claim 1 or 2, wherein the chromophore or fluorophore is detectable by exposure to a laser.
0. 23. The set of duplexes of either of claim 4 or 5, wherein the primers are dna.
0. 24. The set of duplexes of either of claim 4 or 5, wherein the chromophore or fluorophore is detectable by exposure to a high-intensity monochromatic light source.
0. 25. The set of duplexes of either of claim 4 or 5, wherein the chromophore or fluorophore is detectable by exposure to a laser.
0. 26. The set of reagents of claim 7, wherein the primers are dna.
0. 27. The set of reagents of claim 7, wherein the chromophore or fluorophore is detectable by exposure to a high-intensity monochromatic light source.
0. 28. The set of reagents of claim 7, wherein the chromophore or fluorophore is detectable by exposure to a laser.
0. 29. The polynucleotide of any of claims 14 to 16, wherein the primer is dna.
0. 30. The polynucleotide of any of claims 14 to 16, wherein the chromophore or fluorophore is detectable by exposure to a high-intensity monochromatic light source.
0. 31. The polynucleotide of any of claims 14 to 16, wherein the chromophore or fluorophore is detectable by exposure tc a laser.
0. 32. The duplex of any of claims 11 to 13, wherein the primer is dna.
0. 33. The duplex of any of claims 11 to 13, wherein the chromophore or fluorophore is detectable by exposure to a high-intensity monochromatic light source.
0. 34. The duplex of any of claims 11 to 13, wherein the chromophore or fluorophore is detectable by exposure to a laser.
0. 35. The duplex of either of claim 1 or 2, wherein the chromophore or fluorophore is covalently coupled to the primer through an amine linkage.
0. 36. The set of duplexes of either of claim 4 or 5, wherein the chromophore or fluorophore is covalently coupled to the primer through an amine linkage.
0. 37. The set of reagents of claim 7, wherein the chromophore or fluorophore is covalently coupled to the primer through an amine linkage.
0. 38. The duplex of either of claim 1 or 2, wherein the chromophore or fluorophore is covalently coupled to the primer at its 5′ end.
0. 39. The set of duplexes of either of claim 4 or 5, wherein the chromophore or fluorophore is covalently coupled to the primer at its 5′ end.
0. 40. The set of reagents of claim 7, wherein the chromophore or fluorophore is covalently coupled to the primer at its 5′ end.
0. 41. The polynucleotide of claim 3, wherein the chromophore or fluorophore is covalently coupled to the primer through an amine linkage.
0. 42. The polynucleotide of claim 3, wherein the chromophore or fluorophore is covalently coupled to the primer at its 5′ end.
0. 43. The polynucleotide of claim 3, wherein the chromophore or fluorophore is detectable by exposure to a laser.
0. 44. The set of polynucleotides of claim 6, wherein the primers are dna.
0. 45. The set of polynucleotides of claim 6, wherein the chromophore or fluorophore is detectable by exposure to a high-intensity monochromatic light source.
0. 46. The set of polynucleotides of claim 6, wherein the chromophore or fluorophore is detectable by exposure to a laser.
0. 47. The set of polynucleotides of claim 6, wherein the chromophore or fluorophore is covalently coupled to the primer through an amine linkage.
0. 48. The set of polynucleotides of claim 6, wherein the chromophore or fluorophore is covalently coupled to the primer at its 5′ end.
0. 49. A duplex comprising an oligonucleotide primer and a template, wherein the primer hybridizes to a specific region of the template and wherein the primer is covalently coupled to a chromophore or fluorophore so as to allow chain extension by a polymerase.
0. 50. A plurality of identical oligonucleotide primers of defined length and base sequences wherein each primer is covalently coupled to a fluorophore or chromophore so as to allow chain extension by a polymerase.
0. 51. The plurality of claim 50 wherein said primers have a free 3′ hydroxyl group.
0. 52. The plurality of claim 51 wherein the chromophore or fluorophore is covalently coupled to the primer at its 5′ end.
0. 53. The plurality of claim 50 wherein said primers are coupled to said fluorophore or chromophore by an amine linkage.
0. 54. A composition comprising the plurality of claim 50.
0. 55. The composition of claim 54 further comprising a buffer.
0. 56. A set of reagents comprising the plurality of claim 50 and a polymerase.
0. 57. A set of reagents comprising two or more pluralities of oligonucleotide primers of claim SO wherein each plurality has a different emission spectra.
0. 58. A plurality of single-stranded labeled polynucleotides produced by the method comprising the steps of hybridizing the plurality of oligonucleotide primers of claim 50 to a template thereby forming a plurality of duplexes; extending the primers of said duplexes by a polymerase thereby forming labeled polynucleotides; and separating said labeled polynucleotides from said duplexes.
0. 59. A set of single stranded labeled polynucleotides comprising two or more pluralities of polynucleotides of claim 58, wherein each plurality has a different emission spectra.
0. 60. The plurality of claim 50 wherein the chromophore or fluorophore is detectable by exposure to a high-intensity monochromatic light source.
0. 61. The plurality of claim 50 wherein the chromophore or fluorophore is detectable by exposure to a laser.
0. 63. The method of claim 62, further comprising separating said labeled extension product from said duplex.
0. 65. The method of claim 64 or claim 62, wherein the fluorophore is covalently coupled to the oligonucleotide through an amine linkage.
0. 68. The method of claim 64, wherein the extension products comprise a terminal nucleotide having any one of four different types of terminal base components, wherein substantially all molecules of the same set of labeled extension products have the same type of terminal base component, and substantially all molecules of different sets of labeled extension products have different types of terminal base components.
0. 69. The composition of claim 67, wherein the oligonucleotides comprise a terminal nucleotide having any one of four different types of terminal base components, wherein substantially all oligonucleotide molecules of the same set have the same type of terminal base component, and substantially all oligonucleotide molecules of different sets have different types of terminal base components.
0. 70. The method of claim 62, wherein substantially all molecules of the labeled extension product individually comprise a single fluorescent nucleotide.
0. 71. The method of claim 64, wherein substantially all molecules of the labeled extension products individually comprise a single fluorescent nucleotide.
0. 72. The mixture of claim 66, wherein substantially all oligonucleotide molecules individually comprise a single fluorescent nucleotide.
0. 73. The composition of claim 67, wherein substantially all oligonucleotide molecules of each set individually comprise a single fluorescent nucleotide.
0. 74. The method of claim 62, wherein substantially all molecules of the labeled extension product are individually coupled to a fluorophore by a single covalent linkage.
0. 75. The method of claim 64, wherein substantially all molecules of the labeled extension products are individually coupled to a fluorophore by a single covalent linkage.
0. 76. The mixture of claim 66, wherein substantially all oligonucleotide molecules are individually coupled to a fluorophore by a single covalent linkage.
0. 77. The composition of claim 67, wherein substantially all oligonucleotide molecules of each set are individually coupled to a fluorophore by a single covalent linkage.
0. 78. The method of claim 68, wherein substantially all molecules of the labeled extension products individually comprise a single fluorescent nucleotide.
0. 79. The composition of claim 69, wherein substantially all oligonucleotide molecules of each set individually comprise a single fluorescent nucleotide.
0. 80. The method of claim 74, wherein substantially all molecules of the labeled extension product individually are terminally labeled with a fluorophore.
0. 81. The method of claim 75, wherein substantially all molecules of the labeled extension products individually are terminally labeled with a fluorophore.
0. 82. The mixture of claim 76, wherein substantially all oligonucleotide molecules individually are terminally labeled with a fluorophore.
0. 83. The composition of claim 77, wherein substantially all oligonucleotide molecules of each set individually are terminally labeled with a fluorophore.
0. 84. The method of claim 68, wherein substantially all molecules of the labeled extension products individually are terminally labeled with a fluorophore.
0. 85. The composition of claim 69, wherein substantially all oligonucleotide molecules of each set individually are terminally labeled with a fluorophore.
0. 86. The method of claim 70, wherein substantially all molecules of the labeled extension product individually are terminally labeled with a fluorophore.
0. 87. The method of claim 71, wherein substantially all molecules of the labeled extension products individually are terminally labeled with a fluorophore.
0. 88. The mixture of claim 72, wherein substantially all oligonucleotide molecules individually are terminally labeled with a fluorophore.
0. 89. The composition of claim 73, wherein substantially all oligonucleotide molecules of each set individually are terminally labeled with a fluorophore.
0. 90. The method of claim 78, wherein substantially all molecules of the labeled extension products individually are terminally labeled with a fluorophore.
0. 91. The composition of claim 79, wherein substantially all oligonucleotide molecules of each set individually are terminally labeled with a fluorophore.
0. 92. The method of claim 74, wherein substantially all molecules of the labeled extension product individually comprise a 5′ terminal fluorescent nucleotide.
0. 93. The method of claim 75, wherein substantially all molecules of the labeled extension products individually comprise a 5′ terminal fluorescent nucleotide.
0. 94. The mixture of claim 76, wherein substantially all oligonucleotide molecules individually comprise a 5′ terminal fluorescent nucleotide.
0. 95. The composition of claim 77, wherein substantially all oligonucleotide molecules of each set individually comprise a 5′ terminal fluorescent nucleotide.
0. 96. The method of claim 84, wherein substantially all molecules of the labeled extension products individually comprise a 5′ terminal fluorescent nucleotide.
0. 97. The composition of claim 85, wherein substantially all oligonucleotide molecules of each set individually comprise a 5′ terminal fluorescent nucleotide.
0. 98. The method of claim 86, wherein substantially all molecules of the labeled extension product individually comprise a 5′ terminal fluorescent nucleotide.
0. 99. The method of claim 87, wherein substantially all molecules of the labeled extension products individually comprise a 5′ terminal fluorescent nucleotide.
0. 100. The mixture of claim 88, wherein substantially all oligonucleotide molecules individually comprise a 5′ terminal fluorescent nucleotide.
0. 101. The composition of claim 89, wherein substantially all oligonucleotide molecules of each set individually comprise a 5′ terminal fluorescent nucleotide.
0. 102. The method of claim 90, wherein substantially all molecules of the labeled extension products individually comprise a 5′ terminal fluorescent nucleotide.
0. 103. The composition of claim 91, wherein substantially all oligonucleotide molecules of each set individually comprise a 5′ terminal fluorescent nucleotide.
0. 104. The composition of claim 69, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal fluorescent nucleotide.
0. 105. The composition of claim 73, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal fluorescent nucleotide.
0. 106. The composition of claim 79, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal fluorescent nucleotide.
0. 107. The method of claim 68, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide on the complementary strand of dna.
0. 108. The composition of claim 69, wherein substantially all oligonucleotide molecules of each set individually (i) are specifically hybridized to a complementary strand of dna, and (ii) comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide on the complementary strand of dna.
0. 109. The method of claim 71, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide on the complementary strand of dna.
0. 110. The composition of claim 73, wherein substantially all oligonucleotide molecules of each set individually (i) are specifically hybridized to a complementary strand of dna, and (ii) comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide on the complementary strand of dna.
0. 111. The method of claim 75, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide on the complementary strand of dna.
0. 112. The composition of claim 77, wherein substantially all oligonucleotide molecules of each set individually (i) are specifically hybridized to a complementary strand of dna, and (ii) comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide on the complementary strand of dna.
0. 113. The composition of claim 79, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide in a complementary strand of dna.
0. 114. The method of claim 81, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide on the complementary strand of dna.
0. 115. The composition of claim 83, wherein substantially all oligonucleotide molecules of each set individually (i) are specifically hybridized to a complementary strand of dna, and (ii) comprise a 3′ terminal nucleotide that is complementary to a corresponding nucleotide on the complementary strand of dna.
0. 116. The method of claim 68, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 117. The composition of claim 69, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 118. The method of claim 70, wherein substantially all molecules of the labeled extension product individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 119. The method of claim 71, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 120. The composition of claim 73, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 121. The method of claim 74, wherein substantially all molecules of the labeled extension product individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 122. The method of claim 75, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 123. The composition of claim 77, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 124. The method of claim 78, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 125. The composition of claim 79, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 126. The method of claim 80, wherein substantially all molecules of the labeled extension product individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 127. The method of claim 81, wherein substantially all molecules of the labeled extension products individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 128. The composition of claim 83, wherein substantially all oligonucleotide molecules of each set individually comprise a 3′ terminal nucleotide that is adapted to terminate polymerase extension.
0. 129. The composition of claim 69, further comprising a polymerase or nucleotides adapted to terminate polymerase extension.
0. 130. The composition of claim 73, further comprising a polymerase or nucleotides adapted to terminate polymerase extension.
0. 131. The composition of claim 77, further comprising a polymerase or nucleotides adapted to terminate polymerase extension.
0. 132. The composition of claim 79, further comprising a polymerase or nucleotides adapted to terminate polymerase extension.
0. 133. The composition of claim 83, further comprising a polymerase or nucleotides adapted to terminate polymerase extension.
0. 134. The composition of claim 85, further comprising a polymerase or nucleotides adapted to terminate polymerase extension.
0. 135. The composition of claim 89, further comprising a polymerase or nucleotides adapted to terminate polymerase extension.
0. 136. The composition of claim 91, further comprising a polymerase or nucleotides adapted to terminate polymerase extension.
0. 137. The method of claim 68, wherein the four different types of terminal base components are adenosine, guanosine, thymidine and cytosine.
0. 138. The composition of claim 69, wherein the four different types of terminal base components are adenosine, guanosine, thymidine and cytosine.
0. 139. The method of claim 81, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 140. The method of claim 84, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 141. The method of claim 87, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 142. The method of claim 90, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 143. A method of nucleic acid sequence analysis, comprising producing the composition of claim 69, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 144. A method of nucleic acid sequence analysis, comprising producing the composition of claim 73, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 145. A method of nucleic acid sequence analysis, comprising producing the composition of claim 77, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 146. A method of nucleic acid sequence analysis, comprising producing the composition of claim 83, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 147. A method of nucleic acid sequence analysis, comprising producing the composition of claim 85, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 148. A method of nucleic acid sequence analysis, comprising producing the composition of claim 104, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 149. A method of nucleic acid sequence analysis, comprising producing the composition of claim 105, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 150. A method of nucleic acid sequence analysis, comprising producing the composition of claim 108, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 151. A method of nucleic acid sequence analysis, comprising producing the composition of claim 117, and detecting the type of fluorophore on oligonucleotides of the composition.
0. 152. The method of claim 68, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 153. The method of claim 71, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 154. The method of claim 75, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 155. The method of claim 78, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 156. The method of claim 93, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 157. The method of claim 107, wherein the oligonucleotides are fluorescently labeled before being extended.
0. 158. The method of claim 116, wherein the oligonucleotides are fluorescently labeled before being extended.

This application is a continuation of application Ser. No. 08/361,176 filed Dec. 21, 1994, now U.S. Pat. No. 5,821,058 which is a continuation of application Ser. No. 07/898,019, filed Jun. 12, 1992, now abandoned, which is a continuation of application Ser. No. 07/660,160, filed Feb. 21, 1991, now abandoned, which is a continuation of application Ser. No. 07/106,232, filed Oct. 7, 1987, now abandoned, which is a CIP of application Ser. No. 06/722,742, filed Apr. 11, 1985, now abandoned, which is CIP of application Ser. No. 06/689,013,filed Jan. 2, 1985, now abandoned, which is a CIP of application Ser. No. 06/570,973, filed Jan. 16, 1984, now abandoned.

BACKGROUND OF THE INVENTION

The development of reliable methods for sequence analysis of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) has been one of the keys to the success of recombinant DNA and genetic engineering. When used with the other techniques of modern molecular biology, nucleic acid sequencing allows dissection and analysis of animal, plant and viral genomes into discrete genes with defined chemical structure. Since the function of a biological molecule is determined by its structure, defining the structure of a gene is crucial to the eventual manipulation of this basic unit of hereditary information in useful ways. Once genes can be isolated and characterized, they can be modified to produce desired changes in their structure that allow the production of gene products—proteins—with different properties than those possessed by the original proteins. Microorganisms into which the natural or synthetic genes are placed can be used as chemical “factories” to produce large amounts of scarce human proteins such as interferon, growth hormone, and insulin. Plants can be given the genetic information to allow them to survive harsh environmental conditions or produce their own fertilizer.

The development of modem nucleic acid sequencing methods involved parallel developments in a variety of techniques. One was the emergence of simple and reliable methods for cloning small to medium-sized strands of DNA into bacterial plasmids, bacteriophages, and small animal viruses. This allowed the production of pure DNA in sufficient quantities to allow its chemical analysis. Another was the near perfection of gel electrophoretic methods for high resolution separation of oligonucleotides on the basis of their size. The key conceptual development, however, was the introduction of methods of generating size-nested sets of fragments cloned, purified DNA that contain, in their collection of lengths, the information necessary to define the sequence of the nucleotides comprising the parent DNA molecules.

Two DNA sequencing methods are in widespread use. These are the method of Sanger, F., Nicken, S. and Coulson, A. R. Proc. Natl. Acad. Sci. U.S.A. 74, 5463 (1977) and the method of Maxam, A. M. and Gilbert, W. Methods in Enzymology 65, 499-599 (1980).

The method developed by Sanger is referred to as the dideoxy chain termination method. In the most commonly used variation of this method, a DNA segment is cloned into a single-stranded DNA phage such as M13. These phage DNAs can serve as templates for the primed synthesis of the complementary strand by the Klenow fragment of DNA polymerase I. The primer is either a synthetic oligonucleotide or a restriction fragment isolated from the parental recombinant DNA that hybridizes specifically to a region of the M13 vector near the 3″ end of the cloned insert. In each of four sequencing reactions, the primed synthesis is carried out in the presence of enough of the dideoxy analog of one of the four possible deoxynucleotides so that the growing chains are randomly terminated by the incorporation of these “dead-end” nucleotides. The relative concentration of dideoxy to deoxy forms is adjusted to give a spread of termination events corresponding to all the possible chain lengths that can be resolved by gel electrophoresis. The products from each of the four primed synthesis reactions are then separated on individuals tracks of polyacrylamide gels by the electrophoresis. Radioactive tags incorporated in the growing chains are used to develop an autoradiogram image of the pattern of the DNA in each electrophoresis track. The sequence of the deoxynucleotides in the cloned DNA is determined from an examination of the pattern of bands in the four lanes.

The method developed by Maxam and Gilbert uses chemical treatment of purified DNA to generate size-nested sets of DNA fragments analogous to those produced by the Sanger method. Single or double-stranded DNA, labeled with radioactive phosphate at either the 3′ or 5′ end, can be sequenced by this procedure. In four sets of reactions, cleavage is induced at one or two of the four nucleotide bases by chemical treatment. Cleavage involves a three-stage process: modification of the base, removal of the modified base from its sugar, and strand scission at that sugar. Reaction conditions are adjusted so that the majority of end-labeled fragments generated are in the size range (typically 1 to 400 nucleotides) that can be resolved by gel electrophoresis. The electrophoresis, autoradiography, and pattern analysis are carried out essentially as is done for the Sanger method. (Although the chemical fragmentation necessarily generates two pieces of DNA each time it occurs, only the piece containing the end label is detected on the autoradiogram.)

Both of these DNA sequencing methods are in widespread use, and each has several variations.

For each, the length of sequence that can be obtained from a single set of reactions is limited primarily by the resolution of the polyacrylamide gels used for electrophoresis. Typically, 200 to 400 bases can be read from a single set of gel tracks. Although successful, both methods have serious drawbacks, problems associated primarily with the electrophoresis procedure. One problem is the requirement of the use of radiolabel as a tag for the location of the DNA bands in the gels. One has to contend with the short half-life of phosphorus-32, and hence the instability of the radiolabeling reagents, and with the problems of radioactive disposal and handling. More importantly, the nature of autoradiography (the film image of a radioactive gel band is broader than the band itself) and the comparison of band positions between four different gel tracks (which may or may not behave uniformly in terms of band mobilities) can limit the observed resolution of bands and hence the length of sequence that can be read from the gels. In addition, the track-to-track irregularities make automated scanning of the autoradiograms difficult—the human eye can presently compensate for these irregularities much better than computers can. This need for manual “reading” of the autoradiograms is time-consuming, tedious and error-prone. Moreover, one cannot read the gel patterns while the electrophoresis is actually being performed, so as to be able to terminate the electrophoresis once resolution becomes insufficient to separate adjoining bands, but must terminate the electrophoresis at some standardized time and wait for the autoradiogram to be developed before the sequence reading can begin.

An oligonucleotide is a short polymer consisting of a linear sequence of four nucleotides in a defined order. The nucleotide subunits are joined by phosphodiester linkages joining the 3′ hydroxyl moiety of one nucleotide to the 5′ hydroxyl moiety of the next nucleotide. An example of an oligonucleotide is 5′ ApCpGpTpApTpGpGpCp 3′. The letters A, C, G and T refer to the nature of the purine of pyrimidine base coupled at the 1-position of deoxyribose. A, adenine; C, cytosine; G, guanine; T, thymidine. P represents the phosphodiester bond. The structure of a section of an oligonucleotide is shown below.

##STR00001##

The single stranded oligonucleotides of this invention are further characterized by being homogenous with respect to the sequence of the nucleoside subunits and are of uniform molecular weight.

Synthetic oligonucleotides are powerful tools in modern molecular biology and recombinant DNA work. There are numerous applications for these molecules, including a) as probes for the isolation of specific genes based on the protein sequence of the gene product, b) to direct the in vitro mutagenesis of a desired gene, c) as primers for DNA synthesis on a single-stranded template, d) as steps in the total synthesis of genes, and many more, reviewed in Wm. R. Bahl et al, Prog. Nucl. Acid Res. Mol. Biol., 21, 101 (1978).

A very considerable amount of effort has therefore been devoted to the development of efficient chemical methods for the synthesis of such oligonucleotides. A brief review of these methods as they have developed to the present is found in Crockett, G. C., Aldrichimica Acta 16(3), 47–55 (1983). The best methodology currently available utilizes the phosphoramidite derivatives of the nucleosides in combination with a solid phase synthetic procedure, Matteucci et al, J. Am. Chem. Soc., 103, 3185 (1981); and Beaucage et al, M. H. Tet. Lett., 22 (20), 1858-1862 (1981). Oligonucleotides of length up to 30 bases may be made on a routine basis in this matter, and molecules as long as 50 bases have been made. Machines that employ this technology are now commercially available.

There are other reports in the literature of the derivitization of DNA. A modified nucleoside triphosphate has been developed wherein a biotin group is conjugated to an aliphatic amino group at the 5 position of uracil, Langer et al, Proc. Nat. Acad. Sci., U.S.A., 78, 6633-6637 (1981). This nucleotide derivative is effectively incorporate into double stranded DNA. Once in DNA it may be bound by anti-biotin antibody which can then be used for detection by fluorescence or enzymatic methods. The DNA which has had biotin conjugated nucleosides incorporated therein by the method of Langer et al is fragmented into smaller single and double stranded pieces which are heterogeneous with respect to the sequence of nucleoside subunits and variable in molecular weight. Draper and Gold, Biochemistry, 19, 1774-1781 (1980), reported the introduction of aliphatic amino groups by a bisulfite catalyzed transamination reaction, and their subsequent reaction with the fluorescent tag. In Draper and Gold the amino group is attached directly to the pyrimidine base. The amino group so positioned inhibits hydrogen bonding and for this reason, these materials are not useful in hybridization and the like. Chu et al, Nucleic Acid Res. 11(18), 6513-6529 (1983), have reported a method for attaching an amine to the terminal 5′ phosphate of oligonucleotides or nucleic acids.

There are many reasons to want a method for covalently attaching other chemical species to synthetic oligonucleotides. Fluorescent dyes attached to the oligonucleotides permits one to eliminate radioisotopes from the research, diagnostic and clinical procedures in which they are used, and improve shelf-life availability. As described in the assignee's co-pending application for a DNA sequencing machine (Serial No. the synthesis of fluorescent-labeled oligonucleotides permits the automation of the DNA sequencing process.

The invention of the present patent application addresses these and other problems associated with DNA sequencing procedures and is believed to represent a significant advance in the art. The preferred embodiment of the present invention represents a further and distinct improvement.

SUMMARY OF THE INVENTION

Briefly, this invention comprises a novel process for the electrophoetic analysis of DNA fragments produced in DNA sequencing operations wherein chromophores or fluorophores are used to tag the DNA fragments produced by the sequencing chemistry and permit the detection and characterization of the fragments as they are resolved by electrophoresis through a gel. The detection employs an absorption or fluorescent photometer capable of monitoring the tagged bands as they are moving through the gel.

This invention further comprises a novel process for the electrophoretic analysis of DNA fragments produced in DNA sequencing operations wherein a set of four chromophores are used to tag the DNA fragments produced by the sequencing chemistry and permit the detection and characterization of the fragments as they are resolved by electrophoresis through a gel; the improvement wherein the four different fragment sets are tagged with the fluorophores fluorescein, Texas Red, tetramethyl rhodamine, and 7-nitrobenzofurazan.

This invention also includes a novel system for the electrophoretic analysis of DNA fragments produced in DNA sequencing operations comprising:

It is an object of this invention to provide a novel process for the sequence analysis of DNA.

It is another object of our invention to provide a novel system for the analysis of DNA fragments.

More particularly, it is an object of this invention to provide an improved process for the sequence analysis of DNA.

These and other objects and advantages of this invention will be apparent from the detailed description which follows.

BRIEF DESCRIPTION OF THE DRAWINGS

Turning to the drawings:

FIG. 1 is an illustration of one means of end-labeling a DNA fragment with a fluorescent tag. Pst. I and T4 DNA ligase are enzymes commonly used in recombinant DNA research.

FIG. 2 is a block diagram of automated DNA sequencer, gel electrophoretic system.

FIG. 3 is a comparison of the type of data produced by DNA sequencing of the sequence shown in FIG. 1.

FIG. 4 is a block diagram of a preferred DNA sequencer according to this invention.

FIG. 5 shows the emission spectra for the four fluorophores used as tags in the preferred embodiment of this invention.

FIG. 6 is a schematic diagram of a possible optical configuration in the detector unit. P, lamp source; L1, objective lens; L2, collimating lens; F1, UV blocking filter; F2, heat blocking filter; F3, band pass excitation filter; F4, long pass emission filter; DM, dichroic mirror; C, polyacrylamide gel; PMT, photomultiplier tube.

FIG. 7 is a schematic diagram of another possible optical configuration in the detector unit. F1 to F4 are bandpass filters centered at the emission maximum of the different dyes. P1 to P4 are photomultiplier tubes. The excitation light is of a wavelength such that it is not transmitted through any of the filters F1 to F4.
DETAILED DESCRIPTION OF THE INVENTION

In the previous methods of DNA sequencing, including those based on the Sanger dideoxy chain termination method, a single radioactive label, phosphorus-32, is used to identify all bands on the gels. This necessitates that the fragment sets produced in the four synthesis reactions be run on separate gel tracks and leads to the problems associated with comparing band mobilities in the different tracks. This problem is overcome in the present invention by the use of a set of four chromophores or fluorophores with different absorption or fluorescent maxima, respectively. Each of these tags is coupled chemically to the primer used to initiate the synthesis of the fragment strands. In turn, each tagged primer is then paired with one of the dideoxynucleotides and used in the primed synthesis reaction with the Klenow fragment of DNA polymerase.

The primers must have the following characteristics. 1) They must have a free 3′ hydroxyl group to allow chain extension by the polymerase. 2) They must be complementary to a unique region 3′ of the cloned insert. 3) They must be sufficiently long to hybridize to form a unique, stable duplex. 4) The chromophore or fluorophore must not interfere with the hybridization or prevent 3′-end extension by the polymerase.

Conditions 1, 2 and 3 above are satisfied by several synthetic oligonucleotide primers which are in general use for Sanger-type sequencing utilizing M13 vectors.

One such primer is the 15 mer 5′ CCC AG TCA CGA CGT T 3′ where A, C, G and T represent the four different nucleoside components of DNA; A, adenosine; C, cytosine; G, guanosine; T, thymidine.

In the preferred embodiment of the present invention a set of four fluorophores with different emission spectra, respectively, are used. These different emission spectra are shown in FIG. 5. Each of these tags is coupled chemically to the primer used to initiate the synthesis of the fragment strands. In turn, each tagged primer is then paired with one of the dideoxynucleotides and used in the primed synthesis reaction with the Klenow fragment of DNA polymerase.

The dyes used must have high extinction coefficients and/or reasonably high quantum yields for fluorescence. They must have well resolved adsorption maxima and/or emission masima. Representative of such amino reactive dues are: fluorescein isothiocyanage (FITC, λmaxEx=495, λmaxEm=520 , ε495≅8×104), tetramethyl rhodamine isothiocyanate (TMRITC, λmaxEx=550, λmaxEm=578, ε550≅4×104), and substituted rhodamine isothiocyanate (XRITC, λ=580, λmaxEm=604, ε580≅8×104)

where λ represents the wavelength in nanometers, Ex is excitation, Em is emission, max is maximum, and ε is the molar extinction coefficient. These dyes have been attached to the M13 primer and the conjugates electrophoresed on a 20% polyacrylamide gel. The labeled,primers are visible by both their absorption and their fluorescence in the gel. All four labeled primers have identical electrophoretic mobilities. The dye conjugated primers retain their ability to specifically hybridize to DNA, as demonstrated by their ability to replace the underivitized oligonucleotide normally used in the sequencing reactions.

The chemistry for the coupling of the chromophoric or fluorophoric tags is described in assignee's copending patent applications Ser. No. 565,010, filed Dec. 20, 1983, now abandoned, and Ser. No. 709,579, filed Mar. 8, 1985, the disclosures of which are expressly incorporated herein by reference. The strategy used is to introduce an aliphatic amino group at the 5′ terminus as the last addition in the synthesis of the oligonucleotide primer. This reactive amino group may then readily be coupled with a wide variety of amino reactive fluorophores or chromophores. This approach aids compatibility of the labeled primers with condition 4 above.

End Labeling of DNA for Use With Maxam/Gilbert Method. In the Maxam/Gilbert method of DNA sequencing, the end of the piece of DNA whose sequence is to be determined must be labeled. This is conventionally done enzymatically using radioactive nucleosides. In order to use the Maxam/Gilbert method in conjunction with the dye detection scheme described in this invention, the DNA piece must be labeled with dyes. One manner in which this maybe accomplished is shown in FIG. 1. Certain restriction endonucleases generate what is known as a 3′ overhang as the product of DNA cleavage. These enzymes generate a “sticky end,” a short stretch of single stranded DNA at the end of a piece of double stranded DNA. This region will anneal with a complementary stretch of DNA, which may be covalently joined to the duplex DNA with the enzyme ligase. In this manner one of the strands is covalently linked to a detectable moiety. This moiety may be a dye, an amino group or a protected amino group (which could be deprotected and reacted with dye subsequent to the chemical reactions).

Sequencing Reactions. The dideoxy sequencing reactions are performed in the standard fashion Smith, A. J. H., Methods in Enzymology 65, 560–580 (1980), except that the scale may be increased if necessary to provide an adequate signal intensity in each band for detection. The reactions are done using a different color primer for each different reaction. No radiolabeled nucleoside triphosphate need be included in the sequencing reaction.

The Maxam/Gilbert sequencing reactions are performed in the usual manner, Gil, S. F. Aldrichimica Acta 16(3), 59–61 (1983), except that the end label is either one or four colored dyes, or a free or protected amino group which may be reacted with dye subsequently.

Detection. There are many different ways in which the tagged molecules which have been separated by length using polyacrylamide gel electrophoresis may be detected. Four illustrative modes are described below. These are i) detection of the fluorescence excited by light of different wavelengths for the different dyes, ii) detection of fluorescence excited by light of the same wavelength for the different dyes, iii) elution of the molecules from the gel and detection by chemiluminescence, and iv) detection by the absorption of light by molecules. In modes i) and ii) the fluorescence detector should fulfill the following requirements. a) The excitation light beam should not have a height substantially greater than the height of a band. This is normally in the range of 0.1 to 0.5 mm. The use of such a narrow excitation beam allows the attainment of maximum resolution of bands. b) The excitation wavelength can be varied to match the absorption maxima of each of the different dyes or can be a single narrow, high intensity light band that excites all four fluorophores and does not overlap with any of the fluorescence emission. c) The optical configuration should minimize the flux of scattered and reflected excitation light to the photodetector 14. The optical filters to block out scattered and reflected excitation light are varied as the excitation wavelength is varied. d) The photodetector 14 should have a fairly low noise level and a good spectral response and quantum efficiency throughout the range of the emission of the dyes (500 to 600 nm for the dyes listed above). e) The optical system for collection of the emitted fluorescence should have a high numerical aperture. This maximizes the fluorescence signal. Furthermore, the depth of field of the collection optics should include the entire width of the column matrix.

Two illustrative fluorescence detection systems are diagrammed in FIGS. 6 and 7. The system in FIG. 6 is compatible with either single wavelength excitation or multi wavelength excitation. For single wavelength excitation, the filter F4 is one of four band pass filters centered at the peak emission wavelength of each of the dyes. This filter is switched every few seconds to allow continual monitoring of each of the four fluorophores. For multi wavelength excitation, the optical elements F3 (excitation filter), DM (dichroic mirror), and F4 (barrier filter) are switched together. In this manner both the excitation light and the observed emission light are varied. The system in FIG. 7 is a good arrangement for the case of single wavelength excitation. This system has the advantage that no moving parts are required, and fluorescence from all four of the dyes may be simultaneously and continuously monitored. A third approach (iii above) to detection is to elute the labeled molecules at the bottom of the gel, combine them with an agent for excitation of chemiluminescence such as 1,2 dioxetane dione, Gill, S. K. Aldrichimica Acta 16(3), 59–61 (1983); Mellbin, G. J. Liq. Chrom. 6(9), 1603–1616 (1983), and flow the mixture directly into a detector which can measure the emitted light at four separate wavelengths. The background signal in chemiluminescence is much lower than in fluorescence, resulting in higher signal to noise ratios and increased sensitivity. Finally, the measurement may be made by measurements of light absorption (iv above). In this case, a light beam of variable wavelength is passed through the gel, and the decrease in the beam intensity due to absorption of light at the different wavelengths corresponding to the absorption maximum of the four dyes, it is possible to determine which dye molecule is in the light path. As disadvantage of this type of measurement is that absorption measurements are inherently less sensitive than fluorescence measurements.

The above-described detection system is interfaced to a computer 16. In each time interval examined, the computer 16 receives a signal proportional to the measured signal intensity at that time for each of the four colored tags. This information tells which nucleotide terminates the DNA fragment of the particular length in the observation window at that time. The temporal sequence of colored bands gives the DNA sequence. In FIG. 3 is shown the type of data obtained by conventional methods, as well as the type of data obtained by the improvements described in this invention.

The following Examples are presented solely to illustrate the invention. In the Examples, parts and percentages are by weight unless otherwise indicated.

EXAMPLE I

Gel electrophoresis. Aliquots of the sequencing reactions are combined and loaded onto a 5% polyacrylamide column 10 shown in FIG. 2 from the upper reservoir 12. The relative amounts of the four different reactions in the mixture are empirically adjusted to give approximately the same fluorescence or absorptive signal intensity from each of the dye DNA conjugates. This permits compensation for differences in dye extinction coefficients, dye fluorescence quantum yields, detector sensitivities and so on. A high voltage is placed across the column 10 so as to electrophorese the labeled DNA fragments through the gel. The labeled DNA segments differing in length by a single nucleotide are separated by electrophoresis in this gel matrix. At or near the bottom of the gel column 10, the bands of DNA are resolved from one another and pass through the detector 14 (more fully described above). The detector 14 detects the fluorescent or chromophoric bands of DNA in the gel and determines their color, and therefore to which nucleotide they correspond. This information yields the DNA sequence.

EXAMPLE II

FIG. 4 shows a block diagram of a DNA sequenator for use with one dye at a time. The beam (4880 A) from an argon ion laser 100 is passed into the polyacrylamide gel tube (sample) 102 by means of a beamsteerer 104. Fluorescence exited by the beam is collected using a low f-number lens 106, passed through an appropriate set of optical filters 108 and 110 to eliminate scattered excitation light and detected using a photomultiplier tube (PMT) 112. The signal is readily detected on a strip chart recorder. DNA sequencing reactions are carried out utlizing a fluorescein labeled oligonucletide primer. The peaks on the chart correspond to fragments to fluorescein labeled DNA of varying lengths synthesized in the sequencing reactions and separated in the gel tube by electrophoresis. Each peak contains on the order of 10−15 to 10−16 moles of fluorescein, which is approximately equal to the amount of DNA obtained per band in an equivalent sequencing gel utilizing radioisotope detection. This proves that the fluorescent tag is not removed or degraded from the oligonucleotide primer in the sequencing reactions. It also demonstrates that the detection sensitivity is quite adequate to perform DNA sequence analysis by this means.

Materials

Fluorescein-5-isothiocyanate (FITC) and Texas Red were obtained from Molecular Probes, Inc. (Junction City, Oreg.). tetramethyl rhodamine isothiocyanate (TMRITC) was obtained from Research Organics, Inc. (Cleveland, Ohio.). 4-fluoro-7-nitro-benzofurazan (NBD-fluoride) was obtained from Sigma Chemical Co. (St. Louis, Mo.). Absorption spectra were obtained on a H/P 8491 spectrophotometer. High performance liquid chromatography was performed on a system composed of two Altex 110A pumps, a dual chamber gradient mixer, Rheodyne injector, Kratos 757 UV detector, and an Axxiom 710 controller.

EXAMPLE III

Addition of 5′-aminothymidine phosphoramidites to oligonucleotides.

The protected 5′-aminothymidine phosphoramidites, 5′-(N-9-fluorenylmethyloxycarbonyl)-5′-amino-5′-deoxy-3′-N, N-diisopropylaminomethoxyphosphinyl thymidine, is coupled to the 5′-hydroxyl of an oligonucleotide using well established DNA synthetic procedures. The solvents and reaction conditions used are identical to those used in oligonucleotide synthesis.

EXAMPLE IV

Dye Conjugation

The basic procedure used for the attachment of fluorescent dye molecules to the amino oligonucleotides is to combine the amino oligonucleotide and the dye in aqueous solution buffered to pH 9, to allow the reaction to stand at room temperature for several hours, and then to purify the product in two stages. The first purification step is to remove the bulk of the unreacted or hydrolyzed dye by gel filtration. The second purification stage is to separate the dye conjugate from unreacted oligonucleotide by reverse phase high performance liquid chromatography. Slight variations upon these conditions are employed for the different dyes, and the specific procedures and conditions used for four particular dyes are given below and in Table 1.

TABLE 1
Reverse Phase HPLC Conditions for
Dye-oligonucleotide Purification
Sample Retention time
PLP-15a 18′
PLP-15-T-NH2b 18′
FITC PLP-15c 27′
NBD PLP-15 25′
TMRITC PLP-15 32′ and 34′d
Texas Red PLP-15 42′
Retention limes shown are for HPLC gradients of 20% solvent B/80% solvent A to 60% solvent B/40% solvent A in 40 min., where solvent A is 0.1 M triethylammonium acetate pH 7.0 and solvent B is 50% acelonitrile, 50% 0.1 M triethylammonium acetate pH 7.0. The column was an Axxiom ODS 5 micron C 18 column #555-102 available from Cole Scientific, Calabasas, CA. This gradient is not optimized tor purification of PLP-15 and PLP-15-T-NH2, but the retention times are included for comparison with the dye primer conjugates.
aPLP-15 is an oligonucleotide primer for DNA sequence analysis in the M13 vectors. Its sequence is 5′CCC AGT CAC GAC FTT 3′.
bPLP-15-T-NH2 is the oligonucleotide PLP-15 to which a 5′-amino-5′-deoxythymidine base has been added to==at the 5′ terminus.
cThe nomenclature Dye PLP-15 signifies the conjugate of PLP-15-T-NH2 and the dye molecule.
dTwo fluorescent oligonucleotide products were obtained with TMRITC. Both were equally effective in sequencing. This is presumed to be due to the two isomers of TMRITC which are present in the commercially available material.

The following procedure is for use with fluorescein isothiocyanate or 4-fluoro-7-nitro-benzofurazan. Amino oligonucleotide (0.1 ml of ˜1 mg/ml oligonucleotide in water) is combined with 1 M sodium carbonate/bicarbonate buffer pH 9 (50 μl), 10 mg/ml dye in dimethylformamide (20 μl) and H2O (80 μl). This mixture is kept in the dark at room temperature for several hours. The mixture is applied to a 10 ml column of Sephadex G-25 (medium) and the colored band of material eluting in the excluded volume is collected. The column is equilibrated and run in water. In control reactions with underivatized oligonucleotides, very little if any dye is associated with the oligonucleotide eluting in the void volume. The colored material is further purified by reverse phase high performance liquid chromatography on an Axxiom C18 column (#555-102, Cole Scientific, Calabasas, Calif.) in a linear gradient of acetonitrile:0.1 M triethylammonium acetate, pH 7.0. It is convenient for this separation to run the column eluant through both a UV detector (for detecting the DNA absorbance) and a fluorescence detector (for detecting the dye moiety). The desired product is a peak on the chromatogram which is both strongly UV absorbing and strongly fluorescent. The dye oligonucleotide conjugates elute at higher acetonitrile concentrations than the oligonucleotides alone, as shown in Table 1. The oligonucleotide is obtained from the high performance liquid chromatographyin solution in a mixture of acetonitrile and 0.1 M triethylammonium acetate buffer. This is removed by lyophilization and the resulting material is redissolved by vortexing in 10 mM sodium hydroxzide (for a minimum amount of time) followed by neutralization with a five fold molar excess (to sodium hydroxide) of Tris buffer, pH 7.5.

The conjugation with Texas Red is identical to that described for fluorescein isothiocyanate and 4-fluoro-7-nitro-benzofurazan, except that:

The conjugation with tetramethyl rhodamine isothiocyanate cyanate is identical to that for Texas Red except that the reaction-is carried out in 10 mM sodium carbonate/bicarbonate buffer, pH 9.0, and 50% dioxane. This increases solubility of the tetramethyl rhodamine and a much higher yield of dye oligonucleotide conjugate is obtained.

In some cases, particularly with the rhodamine-like dyes, a substantial amount of nonspecific binding of dye was observed, as manifested by an inappropriately large dye absorption present in the material eluted from the gel filtration column. In these cases the material was concentrated and reapplied to a second gel filtration column prior to high performance liquid chromatography purification. This generally removed the majority of the noncovalently associated dye.

EXAMPLE V

Properties of Dye-Oligonucleotide Conjugates

The development of chemistry for the synthesis of dye oligonucleotide conjugates allows their use as primers in DNA sequence analysis. Various fluorescent dye primers have been tested by substituting them for the normal primer in DNA sequence analysis by the enzymatic method. An autoradiogram of a DNA sequencing gel in which these dye-conjugated primers were utilized in T reactions in place of the normal oligonucleotide primer was prepared. This autoradiogram was obtained by conventional methods employing α-32P-dCTP as a radiolabel. The autoradiogram showed that the underivitized primer, amino-derivitized primer, and dye conjugated primers all give the same pattern of bands (corresponding to the DNA sequence), indicating that the derivitized primers retain their ability to hybridize specifically to the complementary strand. Secondly, the bands generated using the different primers differ in their mobilities, showing that it is indeed the dye-primers which are responsible for the observed pattern, and not a contaminant of unreacted or underivitized oligonucleotide. Thirdly, the intensity of the bands obtained with the different primers is comparable, indicating that the strength of hybridization is not significantly perturbed by the presence of the dye molecules.

The separations are again carried out in an acrylamide gel column. The beam from an argon ion laser is passed into the polyacrylamide gel tube (sample) by means of a beamsteerer. Fluorescence exited by the beam is collected using a low f-number lens, passed through an appropriate set of optical filters to eliminate scattered excitation light and detected using a photomultiplier tube (PMT). The signal is monitored on a strip chart recorder. DNA sequencing reactions have been carried out utilizing each of the four different dye coupled oligonucleotide primers. In each case a series of peaks are observed on the chart paper. The peaks correspond to fragments of dye labeled DNA of varying lengths synthesized in the sequencing reactions and separated in the gel tube by electrophoresis. Each peak contains of the order of 10−14 to 10−16 moles of dye, which is approximately equal to the amount of DNA obtained per band in an equivalent sequencing gel utilizing radioisotope detection. This proves that the fluorescent tag is not removed or degraded from the oligonucleotide primer in the sequencing reactions. It also demonstrates that the detection sensitivity is quite adequate to perform DNA sequence analysis by this means, and that adequate resolution of the DNA fragments is obtained in a tube gel system.

Having fully described the invention it is intended that it be limited only by the lawful scope of the appended claims.

INVENTORS:

Hood, Leroy E., Smith, Lloyd M., Hunkapiller, Timothy, Hunkapiller, Michael W., Connell, Charles R.

THIS PATENT IS REFERENCED BY THESE PATENTS:
Patent Priority Assignee Title
THIS PATENT REFERENCES THESE PATENTS:
Patent Priority Assignee Title
3906031,
4119521, Apr 25 1977 Stephen, Turner Fluorescent derivatives of activated polysaccharides
4151065, Jan 30 1978 The Regents of the University of California Horizontal slab gel electrophoresis
4318846, Sep 07 1979 Dade Behring Marburg GmbH Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
4373071, Apr 30 1981 Applied Biosystems, LLC Solid-phase synthesis of polynucleotides
4375401, May 20 1981 SEPARATION SCIENCES, INC Electrophoresis system
4401796, Apr 30 1981 Applied Biosystems, LLC Solid-phase synthesis of polynucleotides
4415732, Mar 27 1981 UNIVERSITY PATENTS,INC A CORP OF DE Phosphoramidite compounds and processes
4474948, Apr 08 1982 MILLIPORE CORPORATION, A MASSACHUSETTS CORP Benzazolides and their employment in phosphite ester oligonucleotide synthesis processes
4483964, Jun 20 1983 CHIRON CORPORATION, A DE CORP Reactor system and method for polynucleotide synthesis
4500707, Feb 29 1980 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
4517338, Jun 20 1983 Chiron Diagnostics Corporation Multiple reactor system and method for polynucleotide synthesis
4534647, Feb 23 1981 INSTITUT MOLEKULYARNOI BIOLOGII I BIOKHIMII AKADEMII NAUK KAZAKHSKOR SSR, A CORP OF USSR Apparatus for photometrically scanning gels
4598049, Aug 31 1983 PERKIN-ELMER CETUS INSTRUMENTS, A CT GENERAL PARTNERSHIP General purpose gene synthesizer
4605735, Feb 14 1983 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
4667025, Aug 09 1982 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
4668777, Mar 27 1981 University Patents, Inc. Phosphoramidite nucleoside compounds
4711955, Apr 17 1981 Yale University Modified nucleotides and methods of preparing and using same
4721499, Sep 20 1985 James River Corporation of Virginia Method of producing a rigid paperboard container
4721500, Aug 12 1985 James River Corporation of Virginia Method of forming a rigid paper-board container
4757141, Aug 26 1985 Applied Biosystems, LLC Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
4849513, Dec 20 1983 PERKIN ELMER CORPORATION, THE Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
4855225, Feb 07 1986 Applied Biosystems, LLC Method of detecting electrophoretically separated oligonucleotides
4948882, Feb 22 1983 SYNGENE, INC Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
5015733, Dec 20 1983 California Institute of Technology Nucleosides possessing blocked aliphatic amino groups
5118800, Dec 20 1983 California Institute of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
5118802, Dec 20 1983 California Institute of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
5162654, Feb 01 1991 WISCONSIN ALUMNI RESEARCH FOUNDATION A NON-STOCK, NON-PROFIT CORP OF WISCONSIN Detection apparatus for electrophoretic gels
5171534, Jan 16 1984 California Institute of Technology Automated DNA sequencing technique
5188934, Nov 14 1989 Applied Biosystems, LLC 4,7-dichlorofluorescein dyes as molecular probes
5212304, Aug 26 1985 Applied Biosystems, LLC Amino-derivatized phosphoramidite linking agents
5241060, Jun 23 1982 ENZO DIAGNOSTICS, INC , 40 OAK DRIVE, SYOSSET, NY 11791, A CORP OF NY Base moiety-labeled detectable nucleatide
5258538, Jul 08 1988 Applied Biosystems, LLC 2,3-disubstituted-1,3,2-oxazaphosphacycloalkanes as nucleic acid linking agents
5260433, Jun 23 1982 ENZO DIAGNOSTICS, INC , 40 OAK DRIVE, SYOSSET, NY 11791, A CORP OF NY Saccharide specific binding system labeled nucleotides
5366860, Sep 29 1989 Applied Biosystems, LLC Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
5541313, Feb 22 1983 Molecular Biosystems, Inc. Single-stranded labelled oligonucleotides of preselected sequence
5688655, Feb 10 1988 HOUSEY PHARMACEUTICALS, INC Method of screening for protein inhibitors and activators
5821058, Jan 16 1984 California Institute of Technology Automated DNA sequencing technique
5935783, Sep 20 1995 CHILDREN S HOSPITAL OF PHILADELPHIA Genes mapping in the digeorge and velocardiofacial syndrome minimal critical region
6992180, Jun 23 1982 Enzo Life Sciences, Inc Oligo- or polynucleotides comprising phosphate-moiety labeled nucleotides
7220854, Jun 23 1982 Enzo Life Sciences, Inc. c/o Enzo Biochem, Inc. Sugar moiety labeled nucleotide, and an oligo- or polynucleotide, and other compositions comprising such sugar moiety labeled nucleotides
20020123046,
EP63879,
EP68875,
EP70685,
EP90789,
EP97373,
EP261283,
EP70687,
EP97341,
GB2153356,
JP49126395,
JP57209297,
JP58502205,
JP59126252,
JP5944648,
JP5993100,
JP60161559,
JP60242368,
WO8302277,
WO8303260,
WO8606726,
WO8607361,
ASSIGNMENT RECORDS    Assignment records on the USPTO
//////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Oct 03 1995CONNELL, CHARLES R California Institute of TechnologyASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0271770072 pdf
Oct 04 1995SMITH, LLOYD M California Institute of TechnologyASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0271770072 pdf
Oct 04 1995HUNKAPILLER, MICHAEL W California Institute of TechnologyASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0271770072 pdf
Oct 05 1995HUNKAPILLER, TIM J California Institute of TechnologyASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0271770072 pdf
Oct 12 1995HOOD, LEROY E California Institute of TechnologyASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0271770072 pdf
Mar 13 2003California Institute of Technology(assignment on the face of the patent)
MAINTENANCE FEES AND DATES:    Maintenance records on the USPTO
Date Maintenance Fee Events
May 17 2006ASPN: Payor Number Assigned.
Jul 20 2012ASPN: Payor Number Assigned.
Jul 20 2012RMPN: Payer Number De-assigned.
Aug 15 2012M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jan 10 20154 years fee payment window open
Jul 10 20156 months grace period start (w surcharge)
Jan 10 2016patent expiry (for year 4)
Jan 10 20182 years to revive unintentionally abandoned end. (for year 4)
Jan 10 20198 years fee payment window open
Jul 10 20196 months grace period start (w surcharge)
Jan 10 2020patent expiry (for year 8)
Jan 10 20222 years to revive unintentionally abandoned end. (for year 8)
Jan 10 202312 years fee payment window open
Jul 10 20236 months grace period start (w surcharge)
Jan 10 2024patent expiry (for year 12)
Jan 10 20262 years to revive unintentionally abandoned end. (for year 12)